Understanding the Market | XUANZHUBIO-B rises over 5% again as the company presents clinical phase III research data on palbociclib for breast cancer at the ESMO annual meeting
XUANZHUBIO-B's stock price rose over 5% again, with an increase of 5.12% as of the time of writing, reported at HKD 62.65, with a transaction volume of HKD 23.5573 million. The company presented clinical phase III research data on the combination of palbociclib with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer at the 2025 European Society for Medical Oncology (ESMO). Based on the interim data from this study, the National Medical Products Administration of China accepted the new drug application on May 14, 2025
According to Zhitong Finance APP, XUANZHUBIO-B (02575) has risen over 5% again, with a current increase of 5.12%, priced at HKD 62.65, and a trading volume of HKD 23.5573 million.
In terms of news, XUANZHUBIO previously released a research report stating that it presented the interim analysis results of the clinical phase III (BRIGHT-3) study on the combination of palbociclib with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer in poster form at the 2025 European Society for Medical Oncology (ESMO). Based on the interim data from the BRIGHT-3 study, the National Medical Products Administration of China officially accepted the new drug application for palbociclib combined with aromatase inhibitors (AI) for the treatment of HR+/HER2- advanced breast cancer on May 14, 2025.
Public information shows that palbociclib is a novel CDK2/4/6 inhibitor with a multi-target synergistic mechanism that can effectively inhibit tumor cell proliferation and significantly reduce the common hematological toxicity associated with traditional CDK4/6 inhibitors. In May of this year, palbociclib was approved domestically for use in adult patients with HR+/HER2- advanced or metastatic breast cancer; in combination with fulvestrant for patients who have experienced disease progression after prior endocrine therapy; and as a monotherapy for patients who have experienced disease progression after receiving two or more endocrine therapies and one chemotherapy in the metastatic stage
